Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketek subpoenas

Executive Summary

Frustrated by FDA foot-dragging, House Energy and Commerce Oversight Subcommittee members vote 12-0, Jan. 31, to compel testimony from three FDA criminal investigators and a clinical research assistant involved with a controversial safety study for Sanofi-Aventis' Ketek (telithromycin). The four are expected to testify Feb. 12 as the panel continues its bipartisan probe into how FDA officials reviewed the ketolide antibiotic (1"The Pink Sheet" April 23, 2007, In Brief). A briefing book and documents used to prepare FDA Commissioner Andrew von Eschenbach for a March 22, 2007 hearing on Ketek also is the subject of a subpoena...

You may also be interested in...



Contentious Ketek correspondence

CDER officials reiterate that they did not rely on a fraudulent study to approve Sanofi-Aventis' antibiotic Ketek (telithromycin), in a letter in the April 19 New England Journal of Medicine. In response to a critical perspective article by former FDA reviewer David Ross, the FDAers say they "reviewed the study for safety findings that would have counted 'against the drug,' as is consistent with good review practice," and that data-integrity issues with study 3014 were not provided to an advisory committee so as not to compromise an on-going investigation. Not addressed by the response are Ross' charges that Ketek reviewers were subject to "overt internal pressure ... to alter their conclusions." Ketek's approval is being investigated by the House Energy and Commerce/Oversight and Investigations Subcommittee (1"The Pink Sheet" April 9, 2007, In Brief)...

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

UsernamePublicRestriction

Register

PS049264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel